Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...

Analyst Tim Anderson from Bank of America Securities reiterated a Hold rating on Pfizer (PFE – Research Report) and keeping the price target at ...

Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination ...

The Global Digital Medicine market is experiencing significant growth driven by several key market drivers. Increased smartphone penetration ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

We recently compiled a list of the 15 Best Cheap Stocks to Buy for 2025. In this article, we are going to take a look at ...

Pfizer’s BREAKWATER trial of Braftovi combo regimen demonstrates improved response in patients with BRAF V600E-mutant metastatic colorectal cancer: New York Tuesday, January 28, ...

University of Idaho researchers found that the COVID-19 vaccine does not have any adverse effects on a mother’s breast milk.

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

internal medicine, and rare diseases. Pfizer Inc. (NYSE:PFE) is placing a strong emphasis on enhancing its R&D productivity and pipeline development to drive future growth. In 2024, the company ...